AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager
1 year ago
93
AstraZeneca is boosting its roster with the acquisition of TeneoTwo, which currently has a Phase 1 trial testing its newest treatment for blood cancer, in a deal valued up to 1.27 billion dollars.
The transaction, expected to close in the third quarter of this year, includes TNB-486, which is part of a class of therapeutic antibodies called T-cell engagers. These are emerging as promising treatments for solid tumors and hematologic malignancies. The drug is also being considered for diffuse large B-cell lymphoma and follicular lymphoma. Bringing TeneoTwo into the fold allows Astrazeneca to build on the success of Calquence and further strengthen its pipeline.
Loading comments...
-
LIVE
Ben Shapiro
1 hour agoEp. 1958 - Follow The $$$
3,995 watching -
1:06:32
barstoolsports
1 hour agoMom Life Isn't Always Easy But It's Worth It | Barstool Mother's Day Special
3.48K3 -
33:31
SLS - Street League Skateboarding
2 days agoAll the 9's - SLS San Diego 2024
5.91K3 -
LIVE
TENET Media
54 minutes agoEven SNL Mocking Campus Protesters | Dave Rubin & Isabel Brown
713 watching -
LIVE
OFFICIAL Jovan Hutton Pulitzer Rumble
54 minutes agoCourt of Public Opinion and Why It Is Deployed
174 watching -
LIVE
Midnight's Edge
3 hours agoMark Hamill Debases Star Wars for May 4th, Helldivers 2 make a full PSN Retreat! | MEiTM #557
814 watching -
6:12:53
PudgeTV
14 hours ago🟠Elden Ring - Mourning Death Count Ep 22 | Monday Mourning Mayhem | Weekly Update
15.1K1 -
1:37:41
The Shannon Joy Show
6 hours ago🔥We Were RIGHT About Everything! NYTimes FINALLY Admits Jab Injuries. Exclusive W/Jeffrey Tucker!🔥
16.8K29 -
1:28:44
jeffahern
2 hours agoMonday Madness with Jeff Ahern (9am Pacific)
14.6K3 -
1:17:02
Trumpet Daily
1 hour agoDinesh D'Souza Interview - Trumpet Daily | May 6, 2024
5.22K1